LONDON (Reuters) – AstraZeneca has struck a deal with the commercial arm of a British charity to try and develop a new class of a “cancer metabolism” drugs.

Health

The aim is to exploit the fact cancer cells use energy differently to normal cells, by creating new drugs that control cell metabolism in order to attack tumors whilst sparing normal tissues, the two partners said Sunday.

The three-year alliance will work on a portfolio of projects selected by Cancer Research UK’s commercialization and development arm, Cancer Research Technology (CRT).

AstraZeneca will take the most promising projects into pre-clinical and clinical drug development, sharing the risks and potential rewards with CRT.

(Reporting by Ben Hirschler; Editing by Dan Lalor)

Related posts:

1. Experimental drug kills breast cancer stem cells
2. Pain drug morphine may accelerate cancer growth
3. Lung cancer drug response tied to tumor type: study
4. Gene maps to transform scientists’ work on cancer
5. Cancer drug preserves insulin cells in diabetes